Role of MIF-173G/C and Mbl2 Codon 54A/B Variants in the Risk of Multiple Myeloma: An Association Study

Mustafa       Pehlivan; Ayşe    F.   Nursal; İlknur       Gündeş; Yasemin       Oyacı; Demet       Kıvanç; Sacide       Pehlivan

Abstract

Background: Multiple myeloma (MM) is a malignant disease manifested by the clonal proliferation of atypical plasma cells. Macrophage inhibitory factor (MIF) is one of the pleiotropic regulators in various biological and cellular processes. Mannose-binding lectin (MBL) is a crucial protein involved in the lectin pathway of the immune system.

Objective: We aimed to assess whether variants of MIF and MBL2 genes are associated with MM among a Turkish population.

Methods: We analyzed the MIF-173G/C (rs755622) and MBL2 codon 54A/B (rs1800450) variants in 200 patients with MM and 200 healthy control subjects using a polymerase chain reaction (PCR) followed by restriction endonuclease digestion. There was also an evaluation of the patients undergoing autologous stem-cell transplantation (ASCT) for these variants.

Results: AA and BB genotypes of MBL2 codon 54A/B increased in the patients as compared to the controls (p=0.008, p=0.001, respectively). The subjects carrying AA and BB genotypes of MBL2 were at high risk of development of susceptibility to MM by 7.377 and 8.812 times, respectively. The distribution of MBL2 codon 54A/B alleles was similar between the groups (p>0 .05). There was no statistical difference between the patients and controls in the genotype and allele frequencies of the MIF- 173G/C variant (p>0 .05). The patients undergoing ASCT, MBL2 codon 54A/B AA and BB genotypes also showed association with increased risk for MM (p=0.004, p=0.001, respectively).

Conclusion: As far as we know, this is the first report of the study on an association between these variants and MM in our population. Our results indicate that the MBL2 codon 54A/B variant may be associated with susceptibility to MM.

Keywords: Multiple myeloma, malignant disease, macrophage inhibitory factor, mannose binding lectin, variant, Turkish population.

« Previous Next »

Graphical Abstract

[1] 
Smith, D.; Yong, K. Multiple myeloma. BMJ,  2013, 346, f3863.
[http://dx.doi.org/10.1136/bmj.f3863] [PMID:  23803862] 
[2] 
Rajkumar, S.V. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol.,  2016, 91(7), 719-734.
[http://dx.doi.org/10.1002/ajh.24402] [PMID:  27291302] 
[3] 
Yasasever, V.; Camlica, H.; Duranyildiz, D.; Oguz, H.; Tas, F.; Dalay, N. Macrophage migration inhibitory factor in cancer. Cancer Invest.,  2007, 25(8), 715-719.
[http://dx.doi.org/10.1080/07357900701560695] [PMID:  18058468] 
[4] 
Donn, R.; Alourfi, Z.; De Benedetti, F.; Meazza, C.; Zeggini, E.; Lunt, M.; Stevens, A.; Shelley, E.; Lamb, R.; Ollier, W.E.; Thomson, W.; Ray, D. British Paediatric Rheumatology Study Group. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum.,  2002, 46(9), 2402-2409.
[http://dx.doi.org/10.1002/art.10492] [PMID:  12355488] 
[5] 
Lin, S.; Wang, M.; Liu, X.; Zhu, W.; Guo, Y.; Dai, Z.; Yang, P.; Tian, T.; Dai, C.; Zheng, Y.; Hu, C.; Wei, L.; Dai, Z. Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women. Clin. Exp. Med.,  2017, 17(3), 395-401.
[http://dx.doi.org/10.1007/s10238-016-0439-9] [PMID:  27844180] 
[6] 
Gadjeva, M.; Takahashi, K.; Thiel, S. Mannan-binding lectin--a soluble pattern recognition molecule. Mol. Immunol.,  2004, 41(2-3), 113-121.
[http://dx.doi.org/10.1016/j.molimm.2004.03.015] [PMID:  15159056] 
[7] 
Jack, D.L.; Klein, N.J.; Turner, M.W. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol. Rev.,  2001, 180, 86-99.
[http://dx.doi.org/10.1034/j.1600-065X.2001.1800108.x] [PMID:  11414367] 
[8] 
Sumiya, M.; Super, M.; Tabona, P.; Levinsky, R.J.; Arai, T.; Turner, M.W.; Summerfield, J.A. Molecular basis of opsonic defect in immunodeficient children. Lancet,  1991, 337(8757), 1569-1570.
[http://dx.doi.org/10.1016/0140-6736(91)93263-9] [PMID:  1675710] 
[9] 
Botta, C.; Di Martino, M.T.; Ciliberto, D.; Cucè, M.; Correale, P.; Rossi, M.; Tagliaferri, P.; Tassone, P. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J.,  2016, 6(12)e511
[http://dx.doi.org/10.1038/bcj.2016.118] [PMID:  27983725] 
[10] 
Rajkumar, S.V.; Dimopoulos, M.A.; Palumbo, A.; Blade, J.; Merlini, G.; Mateos, M.V.; Kumar, S.; Hillengass, J.; Kastritis, E.; Richardson, P.; Landgren, O.; Paiva, B.; Dispenzieri, A.; Weiss, B.; LeLeu, X.; Zweegman, S.; Lonial, S.; Rosinol, L.; Zamagni, E.; Jagannath, S.; Sezer, O.; Kristinsson, S.Y.; Caers, J.; Usmani, S.Z.; Lahuerta, J.J.; Johnsen, H.E.; Beksac, M.; Cavo, M.; Goldschmidt, H.; Terpos, E.; Kyle, R.A.; Anderson, K.C.; Durie, B.G.; Miguel, J.F. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol.,  2014, 15(12), e538-e548.
[http://dx.doi.org/10.1016/S1470-2045(14)70442-5] [PMID:  25439696] 
[11] 
Miller, S.A.; Dykes, D.D.; Polesky, H.F. A simple salting outprocedure for extracting DNA from human nucleated cells. Nucleic Acids Res.,  1988, 16, 215.
[http://dx.doi.org/10.1093/nar/16.3.1215] 
[12] 
Akcali, A.; Pehlivan, S.; Pehlivan, M.; Sever, T.; Neyal, M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J. Int. Med. Res.,  2010, 38(1), 69-77.
[http://dx.doi.org/10.1177/147323001003800108] [PMID:  20233515] 
[13] 
Vardar, F.; Pehlivan, S.; Onay, H.; Atlihan, F.; Güliz, N.; Ozkinay, C.; Ozkinay, F. Association between mannose binding lectin polymorphisms and predisposition to bacterial meningitis. Turk. J. Pediatr.,  2007, 49(3), 270-273.
[PMID:  17990579] 
[14] 
Roodman, G.D. Targeting the bone microenvironment in multiple myeloma. J. Bone Miner. Metab.,  2010, 28(3), 244-250.
[http://dx.doi.org/10.1007/s00774-009-0154-7] [PMID:  20127498] 
[15] 
Cao, Y.; Luetkens, T.; Kobold, S.; Hildebrandt, Y.; Gordic, M.; Lajmi, N.; Meyer, S.; Bartels, K.; Zander, A.R.; Bokemeyer, C.; Kröger, N.; Atanackovic, D. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp. Hematol.,  2010, 38(10), 860-867.
[http://dx.doi.org/10.1016/j.exphem.2010.06.012] [PMID:  20619313] 
[16] 
Raman, D.; Baugher, P.J.; Thu, Y.M.; Richmond, A. Role of chemokines in tumor growth. Cancer Lett.,  2007, 256(2), 137-165.
[http://dx.doi.org/10.1016/j.canlet.2007.05.013] [PMID:  17629396] 
[17] 
Bloom, B.R.; Bennett, B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science,  1966, 153(3731), 80-82.
[http://dx.doi.org/10.1126/science.153.3731.80] [PMID:  5938421] 
[18] 
Calandra, T.; Echtenacher, B.; Roy, D.L.; Pugin, J.; Metz, C.N.; Hültner, L.; Heumann, D.; Männel, D.; Bucala, R.; Glauser, M.P. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med.,  2000, 6(2), 164-170.
[http://dx.doi.org/10.1038/72262] [PMID:  10655104] 
[19] 
Bacher, M.; Metz, C.N.; Calandra, T.; Mayer, K.; Chesney, J.; Lohoff, M.; Gemsa, D.; Donnelly, T.; Bucala, R. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA,  1996, 93(15), 7849-7854.
[http://dx.doi.org/10.1073/pnas.93.15.7849] [PMID:  8755565] 
[20] 
Abe, R.; Peng, T.; Sailors, J.; Bucala, R.; Metz, C.N. Regulation of the CTL response by macrophage migration inhibitory factor. J. Immunol.,  2001, 166(2), 747-753.
[http://dx.doi.org/10.4049/jimmunol.166.2.747] [PMID:  11145646] 
[21] 
Lippitz, B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol.,  2013, 14(6), e218-e228.
[http://dx.doi.org/10.1016/S1470-2045(12)70582-X] [PMID:  23639322] 
[22] 
Zheng, Y.; Wang, Q.; Li, T.; Qian, J.; Lu, Y.; Li, Y.; Bi, E.; Reu, F.; Qin, Y.; Drazba, J.; Hsi, E.; Yang, J.; Cai, Z.; Yi, Q. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. J. Natl. Cancer Inst.,  2016, 108(11), 108.
[http://dx.doi.org/10.1093/jnci/djw131] [PMID:  27381622] 
[23] 
Mitchell, R.; Bacher, M.; Bernhagen, J.; Pushkarskaya, T.; Seldin, M.F.; Bucala, R. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J. Immunol.,  1995, 154(8), 3863-3870.
[PMID:  7706726] 
[24] 
Chang, Y.Y.; Greinix, H.T.; Dickinson, A.M.; Wolff, D.; Jackson, G.H.; Andreesen, R.; Holler, E.; Hildebrandt, G.C. G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation. Cytokine,  2009, 48(3), 218-225.
[http://dx.doi.org/10.1016/j.cyto.2009.07.012] [PMID:  19720544] 
[25] 
Shiroeda, H.; Tahara, T.; Shibata, T.; Nakamura, M.; Yamada, H.; Nomura, T.; Hayashi, R.; Saito, T.; Fukuyama, T.; Otsuka, T.; Yano, H.; Ozaki, K.; Tsuchishima, M.; Tsutsumi, M.; Arisawa, T. Functional promoter polymorphisms of macrophage migration inhibitory factor in peptic ulcer diseases. Int. J. Mol. Med.,  2010, 26(5), 707-711.
[PMID: 20878093] 
[26] 
Sreih, A.; Ezzeddine, R.; Leng, L.; LaChance, A.; Yu, G.; Mizue, Y.; Subrahmanyan, L.; Pons-Estel, B.A.; Abelson, A.K.; Gunnarsson, I.; Svenungsson, E.; Cavett, J.; Glenn, S.; Zhang, L.; Montgomery, R.; Perl, A.; Salmon, J.; Alarcón-Riquelme, M.E.; Harley, J.B.; Bucala, R. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum.,  2011, 63(12), 3942-3951.
[http://dx.doi.org/10.1002/art.30624] [PMID:  22127710] 
[27] 
Li, C.; Qiao, B.; Zhan, Y.; Qi, W.; Chen, Z.J. First evidence of genetic association between the MIF-173G/C single-nucleotide polymorphisms and polycystic ovary syndrome. Am. J. Reprod. Immunol.,  2011, 66(5), 416-422.
[http://dx.doi.org/10.1111/j.1600-0897.2011.01011.x] [PMID:  21623990] 
[28] 
Llamas-Covarrubias, M.A. Valle, Bucala, R., Y., RE Navarro-Hernández, R.E., Palafox-Sánchez, C.A., Padilla-Gutiérrez,J.R., Parra-Rojas,I., Bernard-Medina,A.G., Reyes-Castillo,Z., Muñoz-Valle, J.F. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early stage rheumatoid arthritis. Cytokine,  2013, 61, 759-765.
[http://dx.doi.org/10.1016/j.cyto.2012.12.032] [PMID:  23402792] 
[29] 
Ramireddy, L.; Chen, W.T.; Peng, C.T.; Hu, R.M.; Ke, T.W.; Chiang, H.C.; Chang, S.C.; Tsai, F.J.; Lo, W.Y. Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan. J. Clin. Lab. Anal.,  2015, 29(4), 268-274.
[http://dx.doi.org/10.1002/jcla.21763] [PMID:  24840392] 
[30] 
Wang, C.D.; Li, T.M.; Ren, Z.J.; Ji, Y.L.; Zhi, L.S. Contribution of Macrophage Migration Inhibitory Factor -173G/C Gene Polymorphism to the Risk of Cancer in Chinese Population. Asian Pac. J. Cancer Prev.,  2015, 16(11), 4597-4601.
[http://dx.doi.org/10.7314/APJCP.2015.16.11.4597] [PMID:  26107210] 
[31] 
Yuan, Q.; Wang, M.; Wang, M.; Zhang, Z.; Zhang, W. Macrophage migration inhibitory factor gene -173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis. Mol. Biol. Rep.,  2012, 39(3), 3109-3115.
[http://dx.doi.org/10.1007/s11033-011-1075-9] [PMID:  21750916] 
[32] 
Ramireddy, L.; Lin, C.Y.; Liu, S.C.; Lo, W.Y.; Hu, R.M.; Peng, Y.C.; Peng, C.T. Association study between macrophage migration inhibitory factor-173 polymorphism and acute myeloid leukemia in Taiwan. Cell Biochem. Biophys.,  2014, 70(2), 1159-1165.
[http://dx.doi.org/10.1007/s12013-014-0036-z] [PMID:  24879618] 
[33] 
Holmskov, U.; Thiel, S.; Jensenius, J.C. Collections and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol.,  2003, 21, 547-578.
[http://dx.doi.org/10.1146/annurev.immunol.21.120601.140954] [PMID:  12524383] 
[34] 
Eisen, D.P.; Minchinton, R.M. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis.,  2003, 37(11), 1496-1505.
[http://dx.doi.org/10.1086/379324] [PMID:  14614673] 
[35] 
Madsen, H.O.; Garred, P.; Thiel, S.; Kurtzhals, J.A.L.; Lamm, L.U.; Ryder, L.P.; Svejgaard, A. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J. Immunol.,  1995, 155(6), 3013-3020.
[PMID:  7673719] 
[36] 
Terai, I.; Kobayashi, K.; Matsushita, M.; Miyakawa, H.; Mafune, N.; Kikuta, H. Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL. Eur. J. Immunol.,  2003, 33(10), 2755-2763.
[http://dx.doi.org/10.1002/eji.200323955] [PMID:  14515259] 
[37] 
Vekemans, M.; Robinson, J.; Georgala, A.; Heymans, C.; Muanza, F.; Paesmans, M.; Klastersky, J.; Barette, M.; Meuleman, N.; Huet, F.; Calandra, T.; Costantini, S.; Ferrant, A.; Mathissen, F.; Axelsen, M.; Marchetti, O.; Aoun, M. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin. Infect. Dis.,  2007, 44(12), 1593-1601.
[http://dx.doi.org/10.1086/518171] [PMID:  17516403] 
[38] 
Chang, Y.W.; Oh, C.H.; Kim, J.W.; Lee, J.W.; Park, M.J.; Shim, J.J.; Lee, C.K.; Jang, J.Y.; Dong, S.H.; Kim, H.J.; Kim, S.S.; Kim, B.H. Combination of Helicobacter pylori infection and the interleukin 8 -251 T > A polymorphism, but not the mannose-binding lectin 2 codon 54 G > A polymorphism, might be a risk factor of gastric cancer. BMC Cancer,  2017, 17(1), 388.
[http://dx.doi.org/10.1186/s12885-017-3378-2] [PMID:  28558668] 
[39] 
Su, C.; Lin, Y.; Cai, L.; Mao, Q.; Niu, J. Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. Sci. Rep.,  2016, 6, 32147.
[http://dx.doi.org/10.1038/srep32147] [PMID:  27557564] 
[40] 
Michaud, D.S.; Siddiq, A.; Cox, D.G.; Backes, D.M.; Calboli, F.C.; Sughrue, M.E.; Gaziano, J.M.; Ma, J.; Stampfer, M.; Tworoger, S.S.; Hunter, D.J.; Camargo, C.A., Jr; Parsa, A.T. Mannose-binding lectin 2 gene and risk of adult glioma. PLoS One,  2013, 8(4)e61117
[http://dx.doi.org/10.1371/journal.pone.0061117] [PMID:  23637788] 
[41] 
Klostergaard, A.; Steffensen, R.; Møller, J.K.; Peterslund, N.; Juhl-Christensen, C.; Mølle, I. Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms. Eur. J. Haematol.,  2010, 85(1), 58-64.
[http://dx.doi.org/10.1111/j.1600-0609.2010.01443.x] [PMID:  20331735] 
[42] 
Pehlivan, M.; Sahin, H.H.; Ozdilli, K.; Onay, H.; Ozcan, A.; Ozkinay, F.; Pehlivan, S. Gene polymorphisms and febrile neutropenia in acute leukemia--no association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 are associated with the disease in Turkish patients: a preliminary study. Genet. Test. Mol. Biomarkers,  2014, 18(7), 474-481.
[http://dx.doi.org/10.1089/gtmb.2014.0004] [PMID:  24819208] 

Rights & Permissions Print Cite

Article Metrics

17

2

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871530320999200818102731	Print ISSN 1871-5303
Publisher Name Bentham Science Publisher	Online ISSN 2212-3873

Endocrine, Metabolic & Immune Disorders - Drug Targets

Role of MIF-173G/C and Mbl2 Codon 54A/B Variants in the Risk of Multiple Myeloma: An Association Study

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles